SCHEMBL3586473

SCHEMBL3586473

CC1CN(c2nc(Nc3ccc(OCCN(C)C)cc3)c3ncn(-c4cscn4)c3n2)CCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 2/20 0.40
CSNK1D P48730 1/20 0.40
CDK13 Q14004 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
SYK P43405 3/20 0.39
PDGFRA P16234 1/20 0.37
JAK3 P52333 2/20 0.37
LCK P06239 1/20 0.37
BTK Q06187 1/20 0.37
FLT3 P36888 6/20 0.36
PIK3CA P42336 2/20 0.35
MTOR P42345 1/20 0.35
PIK3CG P48736 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
HSF1 Q00613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3582671 0.86 CSNK1D (0.39) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL4443143 0.85 CSNK1D (0.43) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL1591791 0.84 CSNK1D (0.48) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL6015421 0.84 CSNK1D (0.43) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL1590599 0.82 CSNK1D (0.41) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL1590512 0.82 CSNK1D (0.41) CSNK1ECSNK1DCDK13CDK12SYK
SCHEMBL1590602 0.82 CSNK1D (0.41) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL1590513 0.82 CSNK1D (0.41) CSNK1ECSNK1DCDK13CDK12SYK
SCHEMBL1591199 0.82 ABL1 (0.48) CSNK1ECSNK1DCDK13CDK12PDGFRA
SCHEMBL1591031 0.82 CSNK1D (0.41) CSNK1ECSNK1DCDK13CDK12SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US claimed
EP-2124954-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2009-12-02 EP claimed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO claimed
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US disclosed
EP-2124954-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2009-12-02 EP disclosed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES ADK, PNP, DCK CSNK1E 1264/4885CSNK1D 1542/4885CDK13 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.